Physician profile
Brian Patrick Desmond
NPI 1356329809
$9,682.87
in general payments reported to CMS, 2019-2025
18 companies · $6,696 in 2025
The $6,696 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.09 · 2020: $15.45 · 2021: $158 · 2022: $712 · 2023: $734 · 2024: $1,298 · 2025: $6,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,623 · Food and Beverage: $2,549 · Travel and Lodging: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,623.00 |
| Food and Beverage | $2,548.58 |
| Travel and Lodging | $1,556.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $5,258.03 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $2,507.19 | 2022-2025 | Artevo 800 |
| Alcon Vision LLC | $799.27 | 2021-2025 | Argos, Clareon, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $335.17 | 2019-2025 | Tecnis Iol, Amo Phaco Needle, Tecnis Iol |
| Glaukos Corporation | $238.76 | 2023-2024 | Radius, Istent Trabecular Micro-Bypass Stent System, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Abbvie INC. | $160.92 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $59.03 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $56.82 | 2024-2025 | Miebo, Vyzulta, Envista Envy Iol |
| Sight Sciences, INC. | $55.62 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $43.73 | 2019-2021 | |
| Allergan, INC. | $25.80 | 2021 | |
| Dompe US, INC. | $24.74 | 2025 | Oxervate |
| Thea Pharma INC. | $23.33 | 2024 | Iyuzeh |
| Shire North American Group INC | $23.21 | 2019 | |
| Astellas Pharma US INC | $22.24 | 2024 | Izervay |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $18.04 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $15.97 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Desmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.